In the early morning trading session on the 20th, shares of HLB Group affiliates are plunging across the board, drawing keen attention from investors. Some stocks even triggered a trading curb (VI) due to the steep decline.

As of 9:12 a.m. on this day, the key stock prices are as follows. HLB is trading at 31,800 won, down 9.90% from the previous trading day. HLB Pharmaceutical, which saw the largest drop, is down 12.50% to 8,190 won, HLB Life Science is down 10.90% to 2,120 won, and HLB Innovation is down 7.60% to 9,570 won.

Other affiliates are also trending lower in tandem. HLB Global (-6.8%), HLB Panzgen (-8.9%), HLB Genex (-7.9%), HLB Pep (-3.5%), HLB Therapeutics (-9.3%), and HLB Biostep (-4.7%) all turned negative, showing a pattern of selling pressure spreading across the group's stocks in general.

The market interprets this simultaneous decline as the result of shrinking investor sentiment amid expanding volatility in the domestic stock market. However, given that HLB Group stocks have exhibited high volatility driven by U.S. FDA-related issues and expectations for clinical trial results from affiliates, attention is focused on how much of the losses can be recovered following the early-session plunge. The prevailing analysis is that market participants should monitor the morning session trend along with whether selling pressure will persist into the afternoon session.

[This article is not an investment solicitation, and responsibility for investment decisions lies with the investor.]